Tablet Formulation Segmentation for Alogliptin
Solution Overview
Problem
Tableting troubles such as sticking, binding, capping, and laminating occur during the production of tablets containing pharmaceutically active ingredients like Alogliptin, leading to issues with tablet hardness and delayed dissolution, which are not effectively addressed by increasing magnesium stearate or elongating mixing time.
Innovation Solution
Preparation of granules containing the active ingredient and microcrystalline cellulose, and a tableting aid comprising magnesium stearate and microcrystalline cellulose, with specific weight percentages and additives like mannitol and disintegrants, to enhance tablet formability and dissolution properties without causing tableting troubles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If the amount of magnesium stearate is increased to avoid tableting trouble, then tableting trouble is reduced, but tablet formability deteriorates and dissolution is delayed
Solution Approach 1:
The invention divides the formulation into two separate components: (A) a granule containing the pharmaceutically active ingredient and microcrystalline cellulose, and (B) a tableting aid containing magnesium stearate and microcrystalline cellulose. This segmentation allows each component to perform its specific function independently, preventing tableting trouble while maintaining tablet formability and dissolution properties.
Solution Approach 2:
The invention introduces microcrystalline cellulose as an intermediary substance in both components. In component (A), it acts as a binder and filler; in component (B), it works with magnesium stearate to provide lubrication without excessive amounts. This intermediary approach enables controlled lubrication that prevents tableting trouble while preserving tablet integrity and dissolution.
2Reliability
If the mixing time is elongated to avoid tableting trouble, then tableting trouble is reduced, but productivity deteriorates
Solution Approach 1:
By segmenting the formulation into pre-prepared granules (A) and tableting aids (B), the invention eliminates the need for prolonged mixing. The granules can be prepared separately with the active ingredient and microcrystalline cellulose, then quickly combined with the tableting aid in a separate step, significantly reducing overall mixing time while preventing tableting trouble.
Solution Approach 2:
The invention performs preliminary preparation of granules (A) containing the active ingredient and microcrystalline cellulose before the final tableting step. This preliminary action allows the critical binding and filler functions to be established in advance, so that only a brief mixing step is needed when combining with the tableting aid, thereby maintaining productivity.
3Reliability
If the amount of magnesium stearate is increased to avoid tableting trouble, then tableting trouble is reduced, but tablet hardness decreases
Solution Approach 1:
The invention segments the magnesium stearate into a separate tableting aid component (B) rather than mixing it extensively with the active ingredient granules (A). This segmentation allows precise control over the lubricant distribution, providing sufficient magnesium stearate to prevent tableting trouble while limiting its overall amount to preserve tablet hardness.
Solution Approach 2:
The invention optimizes the concentration and distribution parameters of magnesium stearate by formulating it in a separate component with controlled microcrystalline cellulose content (2-20 wt%). This parameter control ensures adequate lubrication for preventing tableting trouble while maintaining tablet hardness through precise formulation ratios.
Data Source
AI summary
The present invention provides a tablet without causing a tableting trouble, which is superior in the tablet formability, dissolution property of pharmaceutically active ingredient, and the like.